Pachynski, Russell K.
Washington University in St. Louis
3 papers on CoChatORCID 0000-0002-8966-7631
Most cited papers
- Verified
Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell
Cancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research
Cited by 406
- Verified
1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Shen, J., Pachynski, R., Nordquist, L. T., Adra, N., Bilen, M. A., Aggarwal, R., Reichert, Z., Schweizer, M., Iravani, A., Aung, S., et al. (2023) · Annals of Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 24
- Verified
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025) · Current Treatment Options in Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 18
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free